Etokimab in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)



Status:Recruiting
Conditions:Sinusitis
Therapuetic Areas:Otolaryngology
Healthy:No
Age Range:18 - 65
Updated:3/27/2019
Start Date:December 27, 2018
End Date:December 2019
Contact:Kham Phenis
Email:info@anaptysbio.com
Phone:858-362-6295

Use our guide to learn which trials are right for you!

A Phase 2 Double-Blind, Placebo-Controlled Multi-dose Study to Investigate Etokimab (ANB020) Activity in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps

A study to evaluate the safety and efficacy multiple doses of Etokimab in subjects with
Chronic Rhinosinusitis with Nasal Polyps.

This study is a Phase II, randomized, placebo controlled, double-blind, multi-dose study to
evaluate the efficacy and safety of Etokimab in subjects with Chronic Rhinosinusitis with
Nasal Polyps.

Inclusion Criteria:

- Clinically confirmed diagnosis of CRSwNP

- Nasal polyp score ≥ 5 out of a maximum score for both nostrils (with at least a score
of 2 for each nostril).

- SNOT-22 score > 7.

- Presence of at least two of the following symptoms prior to screening: nasal
blockade/obstruction/congestion or nasal discharge (anterior/posterior nasal drip);
facial pain/pressure; reduction or loss of smell

- Body mass index (BMI) of 18 to 38 kg/m2 (inclusive) and total body weight >50 kg (110
lb). BMI=weight (kg)/(height [m2]).

Exclusion Criteria:

- Use of investigational drugs or prohibited therapy for this study within 2 months
before screening or 5 half-lives, whichever is longer.

- Have experienced severe life threatening anaphylactic reactions.

- Participation in any interventional study for the treatment of CRSwNP in the 6 months
before screening.

- If female, is pregnant or lactating, or intend to become pregnant during the study
period.

- History (or suspected history) of alcohol or substance abuse.

- Current smokers or former smokers with a smoking history of ≥15 pack years. If a
patient has less than 15 pack years smoking history, he or she should have quit
smoking at least 6 months before screening to enroll in the study.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.
We found this trial at
14
sites
Colorado Springs, Colorado 80909
802
mi
from 91732
Colorado Springs, CO
Click here to add this to my saved trials
Baltimore, Maryland 21236
2308
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
2310
mi
from 91732
Boca Raton, FL
Click here to add this to my saved trials
Brandon, Florida 33511
?
mi
from 91732
Brandon, FL
Click here to add this to my saved trials
Canoga Park, California 91304
?
mi
from 91732
Canoga Park, CA
Click here to add this to my saved trials
Greenfield, Wisconsin 53228
1723
mi
from 91732
Greenfield, WI
Click here to add this to my saved trials
Matthews, North Carolina 28105
2109
mi
from 91732
Matthews, NC
Click here to add this to my saved trials
628
mi
from 91732
Medford, OR
Click here to add this to my saved trials
North Charleston, South Carolina 29420
2172
mi
from 91732
North Charleston, SC
Click here to add this to my saved trials
Oklahoma City, Oklahoma 73120
1162
mi
from 91732
Oklahoma City, OK
Click here to add this to my saved trials
?
mi
from 91732
Sacramento, CA
Click here to add this to my saved trials
101
mi
from 91732
San Diego, CA
Click here to add this to my saved trials
1250
mi
from 91732
Tulsa, OK
Click here to add this to my saved trials
Tulsa, Oklahoma 74136
1250
mi
from 91732
Tulsa, OK
Click here to add this to my saved trials